PRNAF ALTERITY THERAPEUTICS LTD
Price Chart
Executive Summary
Alterity Therapeutics appointed Ann Cunningham, a seasoned biotech executive with extensive experience in neurodegenerative diseases and commercial strategy, to its Board of Directors as an independent Non-Executive Director. This strengthens the company's leadership as it prepares for Phase 3 development of its lead candidate ATH434 in Multiple System Atrophy.
Actionable Insight
Traders should view this as a governance enhancement rather than a fundamental shift; the addition of a commercial expert may improve long-term prospects but does not alter near-term clinical or financial outlook.
Key Facts
- Ann Cunningham appointed to the Board of Directors effective April 17, 2026
- Cunningham brings over 25 years of global pharmaceutical experience, including senior roles at Eli Lilly and Teva Pharmaceuticals
- She has expertise in commercial strategy for neurodegenerative diseases and psychiatry, with a track record in blockbuster drug launches
- Appointment aims to strengthen governance and strategic guidance ahead of Phase 3 trials for ATH434 in MSA
- Cunningham is founder of i Strategy Partners and currently serves on the board of Vistagen Therapeutics
Financial Impact
No direct financial impact disclosed
Risk Factors
- No immediate impact on clinical timeline or funding position
- Board appointments alone do not guarantee successful commercialization or regulatory outcomes
Market Snapshot
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001437749-26-012602 |
| Document: athe20260417_6k.htm | 0001437749-26-012602 |
| Document: 0001437749-26-012602-index-headers.html | 0001437749-26-012602 |
| Document: 0001437749-26-012602-index.html | 0001437749-26-012602 |
| Document: 0001437749-26-012602.txt | 0001437749-26-012602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Apr 30, 2026
20d ago
|
6-K
| — | awaiting T+5 | — | — |
|
Apr 29, 2026
21d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −3.11% | $0.001100 (−0.00%) |
|
Apr 27, 2026
23d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.40% | $0.001100 (−0.00%) |
|
Apr 22, 2026
28d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.05% | $0.001100 (−0.00%) |
|
Apr 21, 2026
29d ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −1.08% | $0.001100 (−0.00%) |
|
Apr 20, 2026
4w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.91% | $0.001100 (−0.00%) |
|
Apr 17, 2026
4w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −0.55% | $0.001100 (−0.00%) |
|
Apr 15, 2026
5w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −1.64% | $0.001100 (−0.00%) |
|
Apr 1, 2026
7w ago
|
6-K
| $0.001100 $0.001100 | · 0.00% | ▼ −3.77% | $0.001100 (−0.00%) |
|
Mar 30, 2026
7w ago
|
6-K
| $0.000200 $0.001100 | ▲ +450.00% | ▲ +445.70% | $0.001100 (+450.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access